EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

HIV Drug Resistance in Adults Initiating or Reinitiating Antiretroviral Therapy in Uruguay—Results of a Nationally Representative Survey, 2018–2019

Rosa Flieller, Susana Cabrera, Dora Ruchansky, Amalia Girón-Callejas, María Brasesco, Daniel Pérez, Héctor Chiparelli, Claudia García-Morales iD, Daniela Tapia-Trejo, Jessica Monreal-Flores, Giovanni Ravasi, Michael R Jordan und 1 weitere

Viruses · 2023

DOI: 10.3390/v15020490 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2023. Verfasst von Rosa Flieller und 12 weiteren Autor:innen. Beteiligte Einrichtung: Unidad de Virología, Departamento de Laboratorios de Salud Pública, Ministerio de Salud Pública, Montevideo 11600, Uruguay. Hauptthemen laut MEDLINE: HIV Infections, HIV-1. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: CIHR, Mexican Government, Canadian Institutes for Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The first nationally representative cross-sectional HIV drug resistance (HIVDR) survey was conducted in Uruguay in 2018–2019 among adults diagnosed with HIV and initiating or reinitiating antiretroviral therapy (ART). Protease, reverse transcriptase, and integrase genes of HIV-1 were sequenced. A total of 206 participants were enrolled in the survey; 63.2% were men, 85.7% were >25 years of age, and 35.6% reported previous exposure to antiretroviral (ARV) drugs. The prevalence of HIVDR to efavirenz or nevirapine was significantly higher (OR: 1.82, p < 0.001) in adults with previous ARV drug exposure (20.3%, 95% CI: 18.7–22.0%) compared to adults without previous ARV drug exposure (12.3%, 11.0–13.8%). HIVDR to any nucleoside reverse transcriptase inhibitors was 10.3% (9.4–11.2%). HIVDR to ritonavir-boosted protease inhibitors was 1.5% (1.1–2.1%); resistance to ritonavir-boosted darunavir was 0.9% (0.4–2.1%) among adults without previous ARV drug exposure and it was not observed among adults with previous ARV drug exposure. Resistance to integrase inhibitors was 12.7% (11.7–13.8%), yet HIVDR to dolutegravir, bictegravir, and cabotegravir was not observed. The high level (>10%) of HIVDR to efavirenz highlights the need to accelerate the transition to the WHO-recommended dolutegravir-based ART. Access to dolutegravir-based ART should be prioritised for people reporting previous ARV drug exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HIV InfectionsHIV-1MaleAdultHumansFemaleRitonavirCross-Sectional StudiesUruguayAnti-Retroviral AgentsAlkynesCyclopropanesBenzoxazines

Stichwörter der Autor:innen

HIVUruguaydrug resistance surveillance

Substanzen

RitonavirAnti-Retroviral AgentsefavirenzAlkynesCyclopropanesBenzoxazines

Autor:innen und Institutionen

  • Unidad de Virología, Departamento de Laboratorios de Salud Pública, Ministerio de Salud Pública, Montevideo 11600, Uruguay.
  • Programa de ITS-VIH/SIDA, Ministerio de Salud Pública, Montevideo 11200, Uruguay.
  • Facultad de Medicina, Universidad de la República, Montevideo 11800, Uruguay.
  • Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Mexico City 14080, Mexico.
  • Pan American Health Organization, Washington, DC 20037, USA.
  • Division of Geographic Medicine and Infectious Diseases, Tufts Medical Center, Boston, MA 02111, USA.

ORCID-Profile: Claudia García-Morales

Förderung

  • CIHR
  • Mexican Government
  • Canadian Institutes for Health Research

Zitieren

APA

Flieller, R., Cabrera, S., Ruchansky, D., Girón-Callejas, A., Brasesco, M., Pérez, D., Chiparelli, H., García-Morales, C., Tapia-Trejo, D., Monreal-Flores, J., Ravasi, G., Jordan, M. R., & Ávila-Ríos, S. (2023). HIV Drug Resistance in Adults Initiating or Reinitiating Antiretroviral Therapy in Uruguay—Results of a Nationally Representative Survey, 2018–2019. Viruses. https://doi.org/10.3390/v15020490

Vancouver

Flieller R, Cabrera S, Ruchansky D, Girón-Callejas A, Brasesco M, Pérez D, et al. HIV Drug Resistance in Adults Initiating or Reinitiating Antiretroviral Therapy in Uruguay—Results of a Nationally Representative Survey, 2018–2019. Viruses. 2023. doi:10.3390/v15020490

BibTeX
@article{Flieller2023,
  author = {Flieller, Rosa and Cabrera, Susana and Ruchansky, Dora and Girón-Callejas, Amalia and Brasesco, María and Pérez, Daniel and Chiparelli, Héctor and García-Morales, Claudia and Tapia-Trejo, Daniela and Monreal-Flores, Jessica and Ravasi, Giovanni and Jordan, Michael R and Ávila-Ríos, Santiago},
  title = {HIV Drug Resistance in Adults Initiating or Reinitiating Antiretroviral Therapy in Uruguay—Results of a Nationally Representative Survey, 2018–2019},
  journal = {Viruses},
  year = {2023},
  doi = {10.3390/v15020490}
}
Kostenlos starten →